Interstitial lung disease (ILD) is not cancer. It is a group of disorders that cause scarring and inflammation in the lung tissue, making it harder for your lungs to deliver oxygen to your bloodstream. However, the two conditions share overlapping symptoms, can look similar on imaging, and having ILD raises your risk of developing lung cancer over time. That connection is likely why this question comes up so often.
What ILD Actually Is
ILD refers to more than 200 conditions that damage the tissue surrounding the air sacs in your lungs. The damage weakens the walls of these air sacs, triggers inflammation, and leads to a buildup of scar tissue called fibrosis. Over time, this scarring makes the lungs stiffer and less able to exchange oxygen and carbon dioxide. The result is progressive shortness of breath, a dry cough, and eventually, in severe cases, respiratory failure.
The causes fall into a few broad categories. Autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma can direct the immune system to attack lung tissue. Long-term exposure to irritants like silica dust, asbestos fibers, or certain animal droppings can trigger inflammation and scarring. Some medications, including certain chemotherapy drugs and antibiotics, can damage lung tissue directly. And in many cases, no cause is ever identified. The most common of these “unknown cause” forms is idiopathic pulmonary fibrosis (IPF), which tends to be the most serious.
Globally, the number of ILD cases more than doubled between 1990 and 2021, rising from roughly 157,000 to 390,000 new cases per year. Men are affected slightly more often than women.
Why ILD Gets Confused With Cancer
The symptoms of ILD and lung cancer overlap significantly. Both cause persistent cough, chest discomfort, fatigue, and weight loss. This overlap often delays a lung cancer diagnosis in people who already have ILD, because new symptoms get attributed to their existing lung disease rather than investigated as something separate.
Imaging can also be misleading. On a CT scan, the scarring and honeycomb-like patterns typical of ILD can mask or mimic a growing tumor. In one documented case, a lung adenocarcinoma produced honeycombing on a scan that was initially read as inflammatory lung disease. It took a second, larger tissue sample and careful microscopic analysis to identify the cancer cells hiding within the scarred tissue. Pathologists look for specific red flags under the microscope: uniform populations of abnormal cells, cells dividing at high rates, and molecular markers associated with malignant growth. These features distinguish cancer from the disorganized but non-cancerous scarring of ILD.
The Biological Link Between ILD and Cancer
While ILD is not cancer, the underlying biology of the two conditions is surprisingly similar, especially in the case of IPF. Both involve damage to the cells lining the lungs, abnormal repair processes, and a phenomenon where normal lung cells begin transforming into different cell types (a process called metaplasia). In IPF, researchers have found transition zones where this cell transformation progresses from benign changes all the way to invasive cancer, typically in areas right next to heavy scarring.
IPF and lung cancer also share genetic mutations and activate many of the same molecular pathways. Both involve problems with aging-related processes like shortening of telomeres (the protective caps on chromosomes) and reactivation of developmental pathways that should be dormant in adult tissue. In essence, the chronic damage and abnormal repair happening in fibrotic lungs creates an environment where cancer is more likely to take hold.
How Much ILD Raises Cancer Risk
People with IPF face a substantially higher rate of lung cancer than the general population. One study tracking IPF patients found that 3.3% developed lung cancer within the first year, 15% within five years, and nearly 55% within ten years. These are striking numbers, and they help explain why doctors monitor IPF patients closely with regular imaging.
Shared risk factors compound the problem. Smoking, exposure to asbestos, and certain genetic predispositions contribute to both ILD and lung cancer independently. Researchers have worked to separate these overlapping causes, and even after accounting for shared genetics and environmental exposures, ILD itself appears to independently increase cancer risk.
How ILD and Cancer Are Treated Differently
The treatment approaches for ILD and lung cancer are fundamentally different, which is one more reason the distinction matters. ILD treatment focuses on slowing the scarring process and managing inflammation. Many people start on corticosteroids like prednisone to reduce immune-driven inflammation. For IPF specifically, two medications (pirfenidone and nintedanib) can slow the rate at which fibrosis worsens, though neither reverses existing damage. In the most severe cases, lung transplant becomes an option.
Lung cancer treatment depends on the type and stage but typically involves surgery, chemotherapy, radiation, targeted therapy, or immunotherapy. The five-year survival rate for lung cancer overall is about 27%, though this varies enormously by stage: 64% when caught early and localized, dropping to 9% when the cancer has spread to distant organs. Treating lung cancer in someone who also has ILD is particularly challenging because the scarred lungs tolerate surgery and radiation poorly, and some cancer treatments can themselves worsen lung fibrosis.
What the Overlap Means for You
If you have been diagnosed with ILD, the condition itself is not a form of cancer. But it does place you in a higher-risk category for developing lung cancer, particularly if you have IPF. New or worsening symptoms like unexplained weight loss, coughing up blood, or a sudden decline in breathing that doesn’t match your usual disease pattern are worth bringing to your doctor’s attention promptly, since these could signal a new problem rather than progression of the ILD you already have.
If you’re experiencing lung symptoms and don’t yet have a diagnosis, both ILD and lung cancer are possibilities that imaging and tissue sampling can distinguish. The key takeaway is that while ILD and cancer share risk factors, overlapping symptoms, and even some of the same biology, they are fundamentally different diseases requiring different treatments.